2-甲基-7H-吡咯并[3,2-E]嘧啶-4-胺 | 89852-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 中文名称: 2-甲基-7H-吡咯并[3,2-E]嘧啶-4-胺
• 中文别名: 2-甲基-7H-吡咯并[3,2-e]嘧啶-4-胺
• 英文名称: 2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• CAS: 89852-87-9
• 化学式: C₇H₈N₄
• mdl: MFCD12196530
• 分子量: 148.167
• InChiKey: RZHJGZRNZNIZRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲基-7H-吡咯并[3,2-E]嘧啶-4-胺 在 caesium carbonate 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 (2S,4R)-1-(2-(4-amino-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-4-fluoropyrrolidine-2-carboxamide hydrochloride
  参考文献：
  名称：

  [EN] PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS
  [FR] PYRROLOPYRIMIDINE AMINES EN TANT QU'INHIBITEURS DU COMPLÉMENT

  摘要：

  本文披露了式（I）的化合物及其药用盐，这些化合物是裂解系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常裂解系统活动特征的疾病或状况的方法。

  公开号：

  WO2021202977A1

文献信息

• [EN] SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS<br/>[FR] ANALOGUES NUCLÉOSIDIQUES SUBSTITUÉS EN TANT QU'INHIBITEURS DE PRMT5
  申请人：LUPIN LTD

  公开号：WO2021111322A1

  公开（公告）日：2021-06-10

  The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

  该发明涉及式(I)的取代核苷类似物，其药用可接受盐以及用于治疗与PRMT5酶过度表达相关的疾病、疾病或状况的药物组合物。该发明还涉及治疗与PRMT5酶过度表达相关的疾病、疾病或状况的方法。
• [EN] PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF USEFUL AS ANTIVIRAL AGENTS<br/>[FR] NUCLÉOSIDES DE PYRROLOPYRIMIDINE ET ANALOGUES DE CEUX-CI UTILES EN TANT QU'AGENTS ANTIVIRAUX
  申请人：CHIMERIX INC

  公开号：WO2017024310A1

  公开（公告）日：2017-02-09

  The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.

  本公开提供式I、式IA、式IB或式II的吡咯嘧啶嘧啶核苷类似物以及磷脂共轭物和制药组合物，其中Rc和A的定义如本文所述。还提供使用一种或多种式I、式IA、式IB或式II的化合物治疗和/或预防病毒感染和/或与病毒感染相关的疾病或障碍的方法。
• Pyrrolopyrimidine nucleosides and analogs thereof
  申请人：Chimerix, Inc.

  公开号：US10407457B2

  公开（公告）日：2019-09-10

  The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.

  本公开提供了式I、式IA、式IB或式II的吡咯并嘧啶核苷类似物及其磷脂共轭物和药物组合物，其中Rc和A在本文中定义。还提出了用一种或多种式I、式IA、式IB或式II化合物治疗和/或预防病毒感染和/或病毒感染相关疾病或紊乱的方法。
• Small molecule inhibitors of anthrax edema factor
  作者：Guan-Sheng Jiao、Seongjin Kim、Mahtab Moayeri、April Thai、Lynne Cregar-Hernandez、Linda McKasson、Sean O'Malley、Stephen H. Leppla、Alan T. Johnson

  DOI：10.1016/j.bmcl.2017.11.040

  日期：2018.1

  Anthrax is a highly lethal disease caused by the Gram-(+) bacteria Bacillus anthracis. Edema toxin (ET) is a major contributor to the pathogenesis of disease in humans exposed to B. anthracis. ET is a bipartite toxin composed of two proteins secreted by the vegetative bacteria, edema factor (EF) and protective antigen (PA). Our work towards identifying a small molecule inhibitor of anthrax edema factor is the subject of this letter. First we demonstrate that the small molecule probe 50-Fluorosulfonylbenzoyl 50-adenosine (FSBA) reacts irreversibly with EF and blocks enzymatic activity. We then show that the adenosine portion of FSBA can be replaced to provide more drug-like molecules which are up to 1000-fold more potent against EF relative to FSBA, display low cross reactivity when tested against a panel of kinases, and are nanomolar inhibitors of EF in a cell-based assay of cAMP production. (C) 2017 Elsevier Ltd. All rights reserved.
• SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Pfizer Inc.

  公开号：EP3464249B1

  公开（公告）日：2021-08-11